Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: A report from the swedish coronary angiography and angioplasty registry (SCAAR)

Heart

Volumn 97, Issue 18, 2011, Pages 1484-1488

  Koutouzis, Michael ^a   Lagerqvist, Bo ^b   James, Stefan ^b   Omerovic, Elmir ^a   Matejka, Göran ^a   Grip, Lars ^a   Albertsson, Per ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HIRULOG;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SWEDEN; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ANTITHROMBINS; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; RECOMBINANT PROTEINS;

EID: 80052138072     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2011.224709     Document Type: Article

References (16)

1. Antman EM, Hand M, Armstrong PW, et al; Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008;51:210-47.
2. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005;293:1759-65.
3. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients with persistent ST-segment elevation. Eur Heart J 2008;29:2909-45.
4. Lincoff MA, Kleiman NS, Kereiakes DJ, et al. Long term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary interventions: REPLACE-2 randomized trial. JAMA 2004;292:696-703. (Pubitemid 39062523)
5. Stone GW, White HD, Ohman EM, et al; Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007;369:907-19. (Pubitemid 46400858)
6. Stone GW, Witzenbichler B, Guagliumi G, et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30. (Pubitemid 351724451)
7. Akerblom A., James S.K., Koutouzis M., et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J Am Coll Cardiol 2010;56:470-5.
8. Jernberg T., Attebring M.F., Hambraeus K., et al. The Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart 2010;96:1617-21.
9. Dangas G. American College of Cardiology Scientific Sessions. Orlando, FL, 2009.
10. Smit JJ, van Werkum JW, ten Berg J, et al; Ongoing Tirifiban in Myocardial Infarcion Evaluation (ON-TIME) trial investigators. Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. Heart 2010;96:1815-20.
11. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-41. (Pubitemid 28391837)
12. Montalescot G, Barragan P, Wittenberg O, et al; ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
13. Mehilli J, Kastrati A, Schulz S, et al; Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 2009;119:1933-40.
14. Montalescot G, Wiviott SD, Braunwald E, et al; for the TRITON-TIMI 38 Investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TMI 38): double-blind, randomized control trial. Lancet 2009;373:723-31.
15. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
16. Koutouzis M, Albertsson P. Bivalirudin during percutaneous coronary interventions in patients with ST elevation myocardial infarction. Acute Card Care 2010;12:75-6.